NCT07328633Completed
Prehabilitation Plus ERAS in Gastric Cancer Surgery
Effect of Pre-habilitation Combined With Enhanced Recovery After Surgery (ERAS) Versus ERAS Perioperative Management on Clinical Outcomes of Laparoscopic (Robotic) Gastrectomy in Patients With Gastric Cancer Receiving Neoadjuvant Chemotherapy: A Single-center Randomized Controlled Trial
Source: ClinicalTrials.gov · Last updated 9 Jan 2026
Brief summary (registry, in English)
This study aims to evaluate the impact of pre-habilitation combined with Enhanced Recovery After Surgery (ERAS) versus ERAS perioperative management alone on clinical outcomes in patients with gastric cancer undergoing neoadjuvant chemotherapy and laparoscopic (robotic) gastrectomy. The study is a single-center, randomized controlled trial involving patients aged 18-75 years. Participants will be randomly assigned to either a pre-habilitation program plus ERAS or ERAS alone. The primary outcome is the incidence of postoperative complications within 30 days. Secondary outcomes include pathological data, surgical outcomes, patient-reported outcomes, and long-term survival rates.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 136 (actual)
- First submitted
- 19 Sept 2025
- Start date
- 5 Dec 2024
- Primary completion date
- 30 Aug 2025
- Lead sponsor
- The Affiliated Hospital of Qingdao University
- Diseases
- Gastric and esophageal cancer
- NCT number
- NCT07328633
What you commit to
- Study type: Interventional
- Participants enrolled: 136
- From 5 Dec 2024 to the primary completion date, 30 Aug 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Concomitant tumors requiring surgery
- Emergency surgery for tumor complications,
Other illness
- Severe infections
Lab values
- Severe cardiac (LVEF\<30% or NYHA IV)
Other
- Severe hepatic or renal dysfunction (Child-Pugh ≥10; CrCl\<25 ml/min)
- Recent cerebrovascular events
Who the study is looking for
- Age:18-75 years
- ECOG:0-2
- ASA:I-III
- Histologically confirmed gastric adenocarcinoma (cT3-4aN+M0)
- Fit for radical surgery after MDT
- Negative pregnancy test within one month
- Non-pregnant or non-lactating
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The Affiliated Hospital of Qingdao University Coordinator of this site? Confirm its status | Qingdao | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.